Clinical Trials Logo

Breastcancer clinical trials

View clinical trials related to Breastcancer.

Filter by:

NCT ID: NCT04993040 Completed - Breastcancer Clinical Trials

A PK Study of Oraxol in Breast Cancer Patients

Start date: April 22, 2019
Phase: Phase 1
Study type: Interventional

This is a multicenter, open-label, single-arm PK study in approximately 24 breast cancer patients for whom paclitaxel treatment is indicated.

NCT ID: NCT04168957 Recruiting - Breastcancer Clinical Trials

An Extension Study to Provide Oraxol to Patients Who Completed KX-ORAX-007

Start date: October 25, 2017
Phase: Phase 1
Study type: Interventional

KX-ORAX-008 is an extension study of patients who completed KX-ORAX-007 without disease progression as defined by (RECIST) v 1.1 and who wish to continue Oraxol treatment.

NCT ID: NCT03165955 Completed - Breastcancer Clinical Trials

A Clinical Study to Determine the Pharmacokinetics of Oraxol in Breast Cancer Patients

Start date: May 9, 2017
Phase: Phase 1
Study type: Interventional

This is a multicenter, open-label, single-arm PK study in patients for whom paclitaxel treatment is indicated.

NCT ID: NCT03121248 Recruiting - Breastcancer Clinical Trials

Outcome of 15 Versus 5 Fractions in Adjuvant Breast Radiotherapy in Women Over 65 Years

HAI-5-III
Start date: February 15, 2017
Phase: N/A
Study type: Interventional

This study will evaluate the effect of highly accelerated external beam radiotherapy (EBRT) in 5 fractions over 10 days compared to 15 fractions over 3 weeks for early as well as locally-advanced stage breast cancer. Primary endpoint will be chronic toxicity (breast deformation and retraction). Secondary endpoints are acute toxicity, loco-regional and distant tumor control, patient reported QoL and cosmetic satisfaction. Patients with lymph node irradiation will be closely monitored for radiation induced plexopathy.

NCT ID: NCT03066947 Completed - Breast Neoplasm Clinical Trials

SV-BR-1-GM in Metastatic or Locally Recurrent Breast Cancer

Start date: May 5, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

This is a single arm, open label study of SV-BR-1-GM, a targeted immunotherapy for breast cancer. Eligible patients will have histological confirmation of breast cancer with recurrent and/or metastatic lesions. The treatment regimen includes a pre-treatment with low-dose cyclophosphamide 2-3 days before the inoculation; inoculation in 4 sites on the thighs and upper back; and post-treatment inoculation of Interferon-alpha-2b into the sites of inoculation ~2 and ~4 days after the inoculation. These is repeated every 2 weeks for one month (3 treatments), then monthly for up to one year. Standard tumor assessments are performed at baseline and then every 2-3 months.

NCT ID: NCT03030677 Completed - Breastcancer Clinical Trials

Establishing Technique for PECS2 Catheter Insertion

ETCI
Start date: November 1, 2018
Phase: N/A
Study type: Interventional

The investigators are trying to establish an easy technique for insertion of a catheter for continuous infusion while performing pectoral type 2 (serratus) block, as a post operative pain controlling measure for cases undergoing simple mastectomy, using ultrasound guidence

NCT ID: NCT03023007 Completed - Mastectomy Clinical Trials

Study Evaluating the Efficacy of Loco-regional Anaesthesia PECS on Chronic Pain of a Mastectomy

PECS
Start date: March 30, 2017
Phase: N/A
Study type: Interventional

A non-randomized, mono-centric, prospective interventional study that will assess the efficacy of the loco-regional anesthesia PECS on the rate of chronic pain, 6 month after a patient will have either received a mastectomy or a mastectomy associated with axillary nodes dissection, and/or a reconstruction by prosthesis.

NCT ID: NCT03014076 Completed - Breastcancer Clinical Trials

Immunotherapy Vaccine and Herceptin in Breast Cancer

Start date: January 2008
Phase: Phase 1
Study type: Interventional

The purpose of this trial is to determine if combination immunotherapy with HER2/neu GP2 peptide + GM-CSF vaccine and trastuzumab is safe and immunologically effective in treatment of patients with HER2/neu over-expressing breast cancer in the adjuvant setting. While not a primary endpoint, time to recurrence is measured for enrolled subjects. The objectives of the study are the following: - Assess safety and document local and systemic toxicity to combination immunotherapy with GP2 peptide + GM-CSF vaccine and trastuzumab - Evaluate the in vitro and in vivo immunologic responses to combination immunotherapy of GP2 peptide + GM-CSF vaccine and trastuzumab - Determine maximum tolerated dose and optimal biologic dose for the combination immunotherapy of GP2 peptide + GM-CSF vaccine and trastuzumab

NCT ID: NCT03012893 Completed - Breastcancer Clinical Trials

Identification of C7; Evaluations of 2 Sonographic Methods Using a Transverse and a Sagittal Scan.

Start date: December 2016
Phase: N/A
Study type: Interventional

To determine the accuracy of two techniques (transverse scan and sagittal scan) using ultrasonography to identify C7 spinous process compare to the fluoroscope (standard technique)

NCT ID: NCT03012152 Completed - Breastcancer Clinical Trials

A Comparative Study Between Oncoplastic Breast Surgery and Standard Conservative Surgery:Margin Status and Patient Satisfaction

Start date: September 2012
Phase: N/A
Study type: Interventional

This non randomized study is a comparative study between standard conservative breast surgery and oncoplastic surgery as regard margin status and patient satisfaction.